FAQ/Help |
Calendar |
Search |
Today's Posts |
09-07-2020, 06:41 AM | #1 | ||
|
|||
Member
|
Annovis is attempting to lessen a-synuclein-induced pathogenesis by reducing the synthesis of the a-synuclein protein.
PNT article: First Patients Dosed in Clinical Trial Investigating ANVS401 as Treatment for Parkinson's and Alzheimer's First Patients Dosed in ANVS4 1 Trial for Treating Parkinson's, Alzheimer's Trial Record: Posiphen Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients https://clinicaltrials.gov/ct2/show/NCT04524351 SoPD blog post (background info): Disney's "Attack of the synucleozid from Jupiter" Disney’s “Attack of the synucleozid from Jupiter” – The Science of Parkinson's Posiphen (ANVS401) mode of action: Posiphen is an orally available small molecule drug that inhibits the translation of a-synuclein, by increasing the affinity of Iron Regulatory Protein-1 (IRP1) to the Iron-Response Element (IRE) of the SNCA gene's messenger RNA (mRNA). This represses translation by preventing the association of the mRNA with the ribosome. |
||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||
Phase 1/2a Trial Recruiting ALS Patients to Test AstroRx, Potential New Stem Cell The | ALS News & Research | |||
Phase III Recruiting: Effects of Coenzyme Q10 (CoQ) in PD | Parkinson's Disease Clinical Trials | |||
Phase III Recruiting: Effects of Coenzyme Q10 (CoQ) in PD | Parkinson's Disease | |||
GAD recruiting - another sham surgery trial | Parkinson's Disease | |||
Neurologix Phase II recruiting...GAD | Parkinson's Disease |